Explorer
Pfizer Inc seeks permission for emergency use of vaccine
The Phase 3 study of our COVID19 vaccine candidate has met all primary efficacy endpoints. The study reached 170 confirmed cases of COVID19, with the vaccine candidate BNT162b2 demonstrating 95% efficacy beginning 28 days after the first dose: Pfizer Inc.
The company now has 170 infections on which its data are based. Only eight infections were recorded among volunteers who got the vaccine, while only one got severe disease.
The company now has 170 infections on which its data are based. Only eight infections were recorded among volunteers who got the vaccine, while only one got severe disease.
India
Breaking: Dalit Leader Defends Haldwani Ground Purification, Rejects Claims of Targeting Kharge
BIG UPDATE: Census 2027 Form Lists Caste Question Alongside SC, ST Details in 40-Point Schedule
POLITICAL ROW: Rahul Gandhi's PM Modi Mimicry Sparks BJP Outrage Over Foreign Policy Remarks
Breaking: Jhansi Hoarding Row Escalates as BJP and SP Workers Trade Sharp Allegations
POLITICAL ROW: Haldwani Stage Purification Sparks Dalit Debate After Kharge Rally
View More
Top Headlines
World
Taliban Faces Growing Insurgent Threat Five Years After Seizing Power
News
TV Ad Cap Scrapped: Govt Removes 12-Minute-Per-Hour Limit
News
‘BCI Has Nothing To Do With This’: SC Slams Action Against NALSAR Students
India
80th Independence Day: PM Modi To Hoist Tricolour At Red Fort, ‘Vande Mataram’ First
Trending News
